A 24 Month Open-label, Multicenter, Phase IIIb Study of the Efficacy and Safety of Lucentis (Ranibizumab 0.5mg) in Diabetic Patients With Visual Impairment Due to Macular Oedema Evaluating a Spaced Out Follow-up After Intensive Loading Phase

Trial Profile

A 24 Month Open-label, Multicenter, Phase IIIb Study of the Efficacy and Safety of Lucentis (Ranibizumab 0.5mg) in Diabetic Patients With Visual Impairment Due to Macular Oedema Evaluating a Spaced Out Follow-up After Intensive Loading Phase

Discontinued
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Diabetic macular oedema
  • Focus Registrational; Therapeutic Use
  • Acronyms CONSTELLATION
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 10 Jun 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 09 Dec 2014 Planned End Date changed from 1 Feb 2017 to 1 Jan 2018 as reported by ClinicalTrials.gov record.
    • 09 Dec 2014 Planned primary completion date changed from 1 Feb 2017 to 1 Jan 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top